Rapid and Sensitive Identification of Major Histocompatibility Complex Class I-associated Tumor Peptides by Nano-LC MALDI MS/MS *

Identification of major histocompatibility complex (MHC)-associated peptides recognized by T-lymphocytes is a crucial prerequisite for the detection and manipulation of specific immune responses in cancer, viral infections, and autoimmune diseases. Unfortunately immunogenic peptides are less abundant species present in highly complex mixtures of MHC-extracted material. Most peptide identification strategies use microcapillary LC coupled to nano-ESI MS/MS in a challenging on-line approach. Alternatively MALDI PSD analysis has been applied for this purpose. We report here on the first off-line combination of nanoscale (nano) LC and MALDI TOF/TOF MS/MS for the identification of naturally processed MHC peptide ligands. These peptides were acid-eluted from human leukocyte antigen (HLA)-A2, HLA-A3, and HLA-B/-C complexes separately isolated from a renal cell carcinoma cell lysate using HLA allele-specific antibodies. After reversed-phase HPLC, peptides were further fractionated via nano-LC. This additional separation step provided a substantial increase in the number of detectable candidate species within the complex peptide pools. MALDI MS/MS analysis on nano-LC-separated material was then sufficiently sensitive to rapidly identify more than 30 novel HLA-presented peptide ligands. Peptide sequences contained perfect anchor amino acid residues described previously for HLA-A2, HLA-A3, and HLA-B7. The most promising candidate for a T-cell epitope is an HLA-B7-binding nonamer peptide derived from the tumor-associated gene NY-BR-16. To demonstrate the sensitivity of our approach we characterized peptides binding to HLA-C molecules that are usually expressed at the cell surface at approximately only 10% the levels of HLA-A or HLA-B. In fact, multiple renal cell carcinoma peptides were identified that contained anchor amino acid residues of HLA-Cw5 and HLA-Cw7. We conclude that the nano-LC MALDI MS/MS approach is a sensitive tool for the rapid and automated identification of MHC-associated tumor peptides.

[1]  B. Malissen,et al.  Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. , 2008, Tissue antigens.

[2]  L. Gesualdo,et al.  CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression. , 2004, Blood.

[3]  M. Karas,et al.  Membrane proteome analysis of the green‐sulfur bacterium Chlorobium tepidum , 2004, Electrophoresis.

[4]  R. Becklin,et al.  Development of an LC-MALDI method for the analysis of protein complexes , 2004, Journal of the American Society for Mass Spectrometry.

[5]  A. Purcell,et al.  Immunoproteomics: Mass spectrometry-based methods to study the targets of the immune response. , 2004, Molecular & cellular proteomics : MCP.

[6]  Muthuraman Sathiamurthy,et al.  Toward a Definition of Self: Proteomic Evaluation of the Class I Peptide Repertoire1 , 2004, The Journal of Immunology.

[7]  P. Kloetzel,et al.  Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. , 2004, Current opinion in immunology.

[8]  M. A. Moseley,et al.  Exploiting the complementary nature of LC/MALDI/MS/MS and LC/ESI/MS/MS for increased proteome coverage , 2003, Journal of the American Society for Mass Spectrometry.

[9]  B. Seliger,et al.  Identification of markers for the selection of patients undergoing renal cell carcinoma‐specific immunotherapy , 2003, Proteomics.

[10]  Hans-Georg Rammensee,et al.  Integrated functional genomics approach for the design of patient-individual antitumor vaccines. , 2002, Cancer research.

[11]  Haiyong Han,et al.  Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. , 2002, Cancer research.

[12]  J. Yates,et al.  An automated multidimensional protein identification technology for shotgun proteomics. , 2001, Analytical chemistry.

[13]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[14]  B. Seliger,et al.  Mapping and expression pattern analysis of key components of the major histocompatibility complex class I antigen processing and presentation pathway in a representative human renal cell carcinoma cell line , 2001, Electrophoresis.

[15]  A. Purcell,et al.  The use of post-source decay in matrix-assisted laser desorption/ionisation mass spectrometry to delineate T cell determinants. , 2001, Journal of immunological methods.

[16]  S. Naylor,et al.  Isolation and rapid identification of an abundant self-peptide from class II HLA-DRB1*0401 alleles induced by measles vaccine virus infection. , 2000, Journal of immunological methods.

[17]  Cécile Gouttefangeas,et al.  Identification of tumor‐associated MHC class I ligands by a novel T cell‐independent approach , 2000, European journal of immunology.

[18]  A. Ryo,et al.  Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. , 2000, Anticancer research.

[19]  D. Hochstrasser,et al.  Modeling peptide mass fingerprinting data using the atomic composition of peptides , 1999, Electrophoresis.

[20]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[21]  J. Shabanowitz,et al.  Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.

[22]  P. Brossart,et al.  Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. , 1998, Cancer research.

[23]  F. Momburg,et al.  Generation, intracellular transport and loading of peptides associated with MHC class I molecules. , 1997, Current opinion in immunology.

[24]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[25]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[26]  F Koning,et al.  Identification of a graft versus host disease-associated human minor histocompatibility antigen. , 1995, Science.

[27]  E. Jaffee,et al.  Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption/ionization mass spectrometry. , 1995, Analytical biochemistry.

[28]  M. Lotze,et al.  Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.

[29]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[30]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[31]  P. Parham,et al.  Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C , 1992, The Journal of experimental medicine.

[32]  A Sette,et al.  Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. , 1992, Science.

[33]  R. Henderson,et al.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.

[34]  J R Yates,et al.  Protein sequencing by tandem mass spectrometry. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Roepstorff,et al.  Proposal for a common nomenclature for sequence ions in mass spectra of peptides. , 1984, Biomedical mass spectrometry.

[36]  P. Parham,et al.  Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. , 1981, Human immunology.

[37]  P. Parham,et al.  A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. , 1980, Human immunology.

[38]  C. Barnstable,et al.  Monoclonal Antibodies for Analysis of the HLA System , 1979, Immunological reviews.

[39]  C. Barnstable,et al.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis , 1978, Cell.

[40]  L. Van Kaer.  Major histocompatibility complex class I-restricted antigen processing and presentation. , 2002, Tissue antigens.

[41]  M J O'Hare,et al.  Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. , 2001, Cancer immunity.

[42]  A. Sickmann,et al.  Identification of major histocompatibility complex class II-associated peptides derived from freshly prepared rat Langerhans cells using MALDI-PSD and Edman degradation. , 2000, The Analyst.

[43]  A. D. de Jong.  Contribution of mass spectrometry to contemporary immunology. , 1998, Mass spectrometry reviews.

[44]  F. Dubois,et al.  The Matrix Suppression Effect and Ionization Mechanisms in Matrix‐assisted Laser Desorption/Ionization , 1996 .

[45]  D. Hunt,et al.  Direct analysis of tumor-associated peptide antigens. , 1994, Current opinion in immunology.

[46]  P. Cresswell,et al.  Monoclonal antibody to HLA-A3. , 1982, Hybridoma.